Advances in Hematology / 2016 / Article / Tab 1

Review Article

Choice of Unmanipulated T Cell Replete Graft for Haploidentical Stem Cell Transplant and Posttransplant Cyclophosphamide in Hematologic Malignancies in Adults: Peripheral Blood or Bone Marrow—Review of Published Literature

Table 1

Platforms of conditioning regimens, GVHD prophylaxis, and graft source.

ReferenceConditioning regimenGVHD prophylaxisGraft source

O’Donnell  et al., 2002 [24]FluCyTBIPTCy D +3, Tac MMFBM

Luznik et al., 2008 [25]FluCyTBIPTCy D +3 ± D +4, Tac MMFBM

Symons et al., 2011 [26]BuCy or CyTBIPTCy, Tac MMFBM

Brunstein et al., 2011 [27]FluCyTBIPTCy, Tac MMFBM

Pingali et al., 2014 [28]FluMel Thiotepa or TBIPTCy, Tac MMFBM (94%)

Solomon et al., 2012 [29]FluBuCyPTCy, Tac MMFPBSC

Raiola et al., 2013 [30]FluBu Thiotepa ()
FluTBI 9.9 Gy ()
PTCy, CsA MMFBM

Raj et al., 2014 [31]FluCyTBIPTCy, Tac MMFPBSC

Bhamidipati et al., 2014 [32]FluCyTBIPTCy, Tac MMFPBSC

Castagna et al., 2014 [33]BM FluCyTBI PTCy, Tac MMF 74%
PTCy, CsA MMF 26%
BM (67%)
PBSC FluCyTBIPTCy, Tac MMFPBSC (33%)

Solomon et al., 2015 [34]Flu/TBI (12 Gy)PTCy, Tac MMFPBSC

Bradstock et al., 2015 [35]BM FluCyTBIBM PTCy D +3, Tac MMFBM
PBSC FluCyTBIPBSC PTCy D +3  D +4, Tac MMFPBSC

Gayoso et al., 2013 [36]NMA 77.5%
MA 22.5%
PTCy, CNI, MMFBM 51%
PBSC 49%

Sugita et al., 2015 [37]FluCyBuTBIPTCy, Tac MMFPBSC

BM, bone marrow; Bu, busulfan; CsA, cyclosporine; CNI, calcineurin inhibitor; Cy, cyclophosphamide; D, day; Flu, fludarabine; Mel, melphalan; MMF, mycophenolate; PTCy, posttransplant cyclophosphamide; Tac, tacrolimus; TBI, total body irradiation; PBSC, peripheral blood stem cells.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.